Envoy Medical (COCH) Q2 2024 earnings summary

Executive summary

• Advanced development of the fully implanted Acclaim CI cochlear implant, targeting FDA approval by end of 2026 and IDE application resubmission in Q3 or Q4 2024, with potential pivotal trial enrollment before year-end 2024.

• Early Feasibility Study at Mayo Clinic showed all participants using the device daily with improved quality-of-life scores after 18 months, and no serious or unanticipated adverse device effects.

• Technical improvements addressed system noise, improving signal-to-noise ratio and programming optimization.

• Flexibility of Acclaim implant allows use of hearing aids or consumer electronics in the implanted ear.

• Revenue remains minimal, mainly from legacy Esteem FI-AMEI implants and replacement components.

Financial highlights

• Q2 2024 revenue was $68,000, up 7.9% from Q2 2023, driven by Esteem FI-AMEI unit sales despite lower battery sales; six-month revenue was $127,000, down 9.9% year-over-year.

• Net loss for Q2 2024 was $3.95M, a significant improvement from $13.25M in Q2 2023; six-month net loss was $10.2M, down from $26.5M year-over-year.

• Operating loss for Q2 2024 was $4.86M, up from $4.48M in Q2 2023; six-month operating loss was $9.8M, up 18.3% year-over-year.

• R&D expenses rose 20.3% in Q2 2024 to $2.6M, reflecting increased headcount and clinical preparation.

• Cash at June 30, 2024 was $1.7M, down from $4.2M at year-end 2023.

Outlook and guidance

• Anticipates continued net losses and increased expenses as Acclaim CI development progresses and regulatory submissions are made.

• Expects to resubmit IDE application for pivotal clinical trial in Q3 or Q4 2024, with potential enrollment before year-end 2024; FDA approval for Acclaim CI targeted by end of 2026.

• Ongoing efforts to secure additional capital through equity, debt, or strategic partnerships.